Frontiers Removes Controversial Ivermectin Paper Pre-Publication

A review article containing contested claims about the tropical medicine drug as a COVID-19 treatment was listed as “provisionally accepted” on the journal’s website before being removed this week.

Written byCatherine Offord

| 4 min read

Save for Later

Listen with Speechify

0:00

4:00

ABOVE: © ISTOCK.COM,
BEIJINGSTORY

Update (February 11): The American Journal of Therapeutics has issued expressions of concern on two published papers summarizing ivermectin’s use in COVID-19 patients. One of those papers was a reworked version of the manuscript by Pierre Kory and colleagues that had previously been rejected by Frontiers after editors determined that it contained “a series of strong, unsupported claims.” The other paper was authored by a separate research group. Both expressions of concern cite “allegations of inaccurate data collection and/or reporting” in at least one of the studies included in the reviews. The journal’s editor-in-chief, Peter Manu, tells Retraction Watch that any further action will hinge on the results of independent investigations at other institutions into those allegations.

The editors of Frontiers in Pharmacology have taken down an article about the use of the antiparasitic drug ivermectin in COVID-19 patients. The paper, which was written by members ...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member? Login Here

Meet the Author

Catherine Offord
After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.
View Full Profile